For many small biotechs, the journey to first‑in‑human (FIH) studies is both exhilarating and overwhelming. It’s the moment in which years of discovery work finally meet clinical reality — and where investors expect to see real, defensible progress. But FIH trials have changed dramatically over the past decade. What was once a relatively simple SAD/MAD progression has evolved into a far more complex, multi‑part exercise that demands strategic planning, regulatory awareness, and operational sophistication.
Yet many early‑stage companies still approach FIH as if it were the same straightforward milestone it used to be. The result is predictable: delays, redesigns, regulatory pushback, and unnecessary cost.
Before any protocol is drafted, sponsors need to answer a set of foundational questions: Do the non‑clinical data genuinely support entry into humans? How should the starting dose be justified — NOAEL, MABEL, or a hybrid approach? How many cohorts will be required to characterise safety and pharmacology? And critically, which population makes sense for first dosing — healthy volunteers, patients, or a combination — and what are the risks and benefits of each path? These early decisions shape everything that follows.
Working across hundreds of early‑phase programmes, the hVIVO/CRS team sees the same misconceptions again and again. Here are the most common pitfalls — and how small biotechs can avoid them.
Not anymore.
Twenty years ago, a typical FIH study involved a single‑ascending‑dose (SAD) phase followed by a multiple‑ascending‑dose (MAD) phase. Today, investors, and development teams expect far more integrated designs. Modern FIH protocols often combine:
This shift reflects a broader industry trend: compressing timelines by gathering far more information earlier in development. But it also means FIH trials are no longer “plug‑and‑play.” They demand thoughtful sequencing, strong safety oversight, and the kind of operational flexibility that only experienced early‑phase sites can provide. Many small biotechs underestimate just how much the landscape has evolved — and overestimate how ready they are to manage that level of complexity.
Sponsors frequently arrive with a draft synopsis in hand. Sometimes it’s close. More often, it needs significant refinement.
Common gaps include:
This isn’t a failure — it’s simply the reality of early‑stage biotech. Most small teams don’t have in‑house clinical pharmacologists, medical directors, or regulatory strategists. The most successful biotechs are the ones who seek expert input early — not the ones who assume they already have the answers.
Regional nuance matters — a lot.
US‑based sponsors, in particular, are often surprised by how differently EU and UK authorities evaluate FIH protocols. German regulators, for example, have specific expectations around safety monitoring, dose‑escalation justification, stopping criteria, risk mitigation, patient inclusion in early cohorts, and justification of both the starting and highest planned dose.
A synopsis that looks perfectly reasonable in Boston may raise immediate questions in Berlin. hVIVO/CRS teams routinely help sponsors reshape synopses to align with local expectations — often preventing weeks or months of regulatory delay.
For novel or higher‑risk products, or when non‑clinical data leave areas of uncertainty, early engagement with regulators becomes even more important. Planning and participating in pre‑scientific meetings can clarify expectations, de‑risk key decisions, and ensure that the proposed FIH design is acceptable before a full submission is made.
These regional differences often surprise first‑time sponsors, and they can shape the entire trajectory of an early‑phase programme. FIH success depends not only on strong science, but on knowing exactly what each authority expects to see — and addressing uncertainties proactively.
This is one of the costliest misconceptions.
Small biotechs often approach CRS two years before their planned FIH study — not because they’re ready to start, but because they need:
Early engagement is invaluable because it prevents teams from drifting into designs that aren’t feasible, making promises to investors they can’t keep, underestimating how long key steps will take, or discovering too late that their protocol needs major amendments.
FIH planning should begin long before the IND/CTA submission — not after.
This misconception is especially common among small biotechs with strong scientific founders. They know their molecule better than anyone — but FIH trials require a different kind of expertise.
FIH success depends on:
These are not skills most early‑stage teams have in‑house — nor should they be expected to. The strongest biotechs are the ones who recognise where they need support and build the right partnerships early, especially in the first‑in‑human stage.
FIH trials are not interchangeable across sites. Modern FIH studies require:
hVIVO’s early‑phase units are built for exactly this kind of complexity. Our early‑phase specialist ecosystem brings together the disciplines that matter most at the FIH stage — clinical pharmacology, regulatory‑savvy protocol design, biostatistics, specialised patient access, laboratory science, and tightly coordinated clinical operations — and integrates them into a single, connected workflow. Instead of handing a study off between disconnected vendors and fragmented teams, every part of the programme moves through a team that works together every day, shares data seamlessly, and understands how early‑phase decisions shape later‑phase success.
That’s the advantage of a specialist ecosystem: fewer gaps, fewer surprises, and a smoother, more reliable path through first‑in‑human than a generalist CRO can offer.
First‑in‑human trials are no longer simple milestones. They are complex, high‑stakes clinical investigations that demand strategic planning, regulatory insight, and operational excellence.
Small biotechs that recognise this — and who engage early with experienced early‑phase teams — move faster, reduce risk, and generate cleaner, more decision‑ready data. Those who don’t often learn the hard way.
And this is where an early‑phase specialist ecosystem becomes a genuine advantage. When clinical pharmacology, regulatory expertise, biostatistics, laboratory science, and operational delivery work as one coordinated unit, the entire programme moves with greater confidence and fewer surprises — giving emerging biotechs the support they need to navigate first‑in‑human successfully.